Correlation between vascular endothelial growth factor pathway and immune microenvironment in head and neck squamous
Chao Zhu1, Liqun Gu2, Zelong Liu3
1Department of Stomatology, Xiangya Hospital, Central South University, Changsha, China.
Background:
Immunotherapy is a crucial therapeutic approach in oncology. However, most patients with head and neck squamous cell carcinoma (HNSCC) do not derive benefit from immunotherapy. Vascular endothelial growth factor (VEGF)/VEGF Receptor 2 (VEGFR2) signaling pathway is one of the most important pathways regulating angiogenesis in tumor. The combination of immunotherapy and anti-angiogenic therapy is considered to improve efficacy of immunotherapy. The correlation between VEGF signaling pathway and tumor immune microenvironment in HNSCC patients is unclear.
Methods:
We utilized RNA sequencing and clinical data of HNSCC patients from the TCGA database to study the correlation between VEGF signaling pathway and tumor immune microenvironment, on aspect of immune cell infiltration, immune-related gene expression profiling and immune-related biological pathways.
Results:
We observed that VEGF signaling pathway is positively correlated with immune cell infiltration, immune-related gene expression profiles, and the prognosis of HNSCC patients. The functional enrichment analysis of differentially expressed genes between different VEGF score subtypes detected multiple immune-related biological processes.
Conclusion:
Our findings suggested that combining anti-VEGF signaling pathway agents with immunotherapy, such as immune checkpoint inhibitors (ICI) therapy, may exhibit encouraging benefits in HNSCC.
Insights
The VEGF signaling pathway correlates with immune cell infiltration and prognosis in head and neck squamous cell carcinoma (HNSCC). Combining anti-VEGF agents with immunotherapy may improve HNSCC treatment outcomes.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Immunotherapy is vital in oncology but shows limited efficacy in head and neck squamous cell carcinoma (HNSCC).
- The vascular endothelial growth factor (VEGF)/VEGF Receptor 2 (VEGFR2) pathway regulates tumor angiogenesis.
- Combining immunotherapy with anti-angiogenic therapy is a potential strategy to enhance treatment effectiveness.
Purpose of the Study:
- To investigate the correlation between the VEGF signaling pathway and the tumor immune microenvironment in HNSCC.
- To explore the relationship between VEGF signaling and immune cell infiltration, gene expression, and patient prognosis.
Main Methods:
- Utilized RNA sequencing and clinical data from The Cancer Genome Atlas (TCGA) database for HNSCC patients.
- Analyzed immune cell infiltration, immune-related gene expression profiles, and immune-related biological pathways.
- Performed functional enrichment analysis on differentially expressed genes.
Main Results:
- The VEGF signaling pathway positively correlates with immune cell infiltration in HNSCC.
- VEGF signaling is associated with immune-related gene expression profiles and improved patient prognosis.
- Enrichment analysis revealed multiple immune-related biological processes linked to VEGF pathway activity.
Conclusions:
- The VEGF signaling pathway is a significant factor in the HNSCC tumor immune microenvironment.
- Combining anti-VEGF agents with immunotherapy, like immune checkpoint inhibitors (ICI), may offer therapeutic benefits for HNSCC patients.
More Related Videos
Related Concept Videos
The Tumor Microenvironment
Regulation of Angiogenesis and Blood Supply
Mitogens and the Cell Cycle


